Advertisement
Screener

AYTU BIOPHARMA, INC (AYTU) Increase (Decrease) in Accounts Receivable

2.8 / 5 stars · 68/120 Roast Me

AYTU BIOPHARMA, INC Increase (Decrease) in Accounts Receivable

AYTU BIOPHARMA, INC (AYTU) reported Increase (Decrease) in Accounts Receivable of -$8.38 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-09-22

  • AYTU BIOPHARMA, INC increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was -$1.71M.
  • AYTU BIOPHARMA, INC increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$6.43M, a 161.25% decline year-over-year.
  • AYTU BIOPHARMA, INC increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was -$2.30M, a 201.32% decline year-over-year.
  • AYTU BIOPHARMA, INC increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $2.07M.
  • AYTU BIOPHARMA, INC increase (decrease) in accounts receivable for fiscal 2026 was -$8.38M, a 209.79% decline from fiscal 2025.
  • AYTU BIOPHARMA, INC increase (decrease) in accounts receivable for fiscal 2025 was $7.63M.
  • AYTU BIOPHARMA, INC increase (decrease) in accounts receivable for fiscal 2024 was -$5.20M, a 172.71% decline from fiscal 2023.
  • AYTU BIOPHARMA, INC increase (decrease) in accounts receivable for fiscal 2023 was $7.15M.
Period endIncrease (Decrease) in Accounts Receivable 3 monthIncrease (Decrease) in Accounts Receivable 3 month as first filedIncrease (Decrease) in Accounts Receivable 6 monthIncrease (Decrease) in Accounts Receivable 6 month as first filedIncrease (Decrease) in Accounts Receivable 9 monthIncrease (Decrease) in Accounts Receivable 9 month as first filedIncrease (Decrease) in Accounts Receivable 12 monthIncrease (Decrease) in Accounts Receivable 12 month as first filed
2026-06-30-$1.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22
-$8.14M
derived: sum of 2 quarters · filed 2026-09-22
-$10.45M
derived: sum of 3 quarters · filed 2026-09-22
-$8.38M
10-K · filed 2026-09-22
2026-03-31-$6.43M
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13
-$8.74M
derived: sum of 2 quarters · filed 2026-05-13
-$6.67M
10-Q · filed 2026-05-13
-$11.34M
derived: sum of 4 quarters · filed 2026-09-22
2025-12-31-$2.30M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-03
-$232.00K
10-Q · filed 2026-02-03
-$4.90M
derived: sum of 3 quarters · filed 2026-09-22
$5.60M
derived: sum of 4 quarters · filed 2026-09-22
2025-09-30$2.07M
10-Q · filed 2025-11-13
-$2.60M
derived: sum of 2 quarters · filed 2026-09-22
$7.91M
derived: sum of 3 quarters · filed 2026-09-22
$10.18M
derived: sum of 4 quarters · filed 2026-09-22
2025-06-30-$4.67M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22
$5.83M
derived: sum of 2 quarters · filed 2026-09-22
$8.11M
derived: sum of 3 quarters · filed 2026-09-22
$7.63M
10-K · filed 2026-09-22
2025-03-31$10.51M
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13
$12.78M
derived: sum of 2 quarters · filed 2026-05-13
$12.30M
10-Q · filed 2026-05-13
$6.57M
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$2.27M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-03
$1.79M
10-Q · filed 2026-02-03
-$3.94M
derived: sum of 3 quarters · filed 2026-02-03
-$4.97M
derived: sum of 4 quarters · filed 2026-02-03
2024-09-30-$478.00K
10-Q · filed 2025-11-13
-$6.21M
derived: sum of 2 quarters · filed 2025-11-13
-$478.00K
10-Q · filed 2024-11-13
-$6.62M
derived: sum of 4 quarters · filed 2025-11-13
2024-06-30-$5.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23
-$6.77M
derived: sum of 2 quarters · filed 2025-09-23
-$6.15M
derived: sum of 3 quarters · filed 2025-09-23
-$5.20M
10-K · filed 2025-09-23
-$5.32M
10-K · filed 2024-09-26
2024-03-31-$1.03M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-14
-$414.00K
derived: sum of 2 quarters · filed 2025-05-14
$531.00K
10-Q · filed 2025-05-14
$988.00K
10-Q · filed 2024-05-15
-$4.65M
derived: sum of 4 quarters · filed 2025-05-14
2023-12-31$621.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12
$1.57M
10-Q · filed 2025-02-12
$466.00K
10-Q · filed 2024-02-14
-$3.62M
derived: sum of 3 quarters · filed 2025-02-12
$4.88M
derived: sum of 4 quarters · filed 2025-02-12
2023-09-30$945.00K
10-Q · filed 2023-11-14
-$4.24M
derived: sum of 2 quarters · filed 2024-09-26
$1.68M
10-Q · filed 2024-11-13
$1.89M
derived: sum of 4 quarters · filed 2024-09-26
2023-06-30-$5.18M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26
$3.32M
derived: sum of 2 quarters · filed 2024-09-26
$941.00K
derived: sum of 3 quarters · filed 2024-09-26
$7.15M
10-K · filed 2024-09-26
2023-03-31$8.50M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-15
$6.12M
derived: sum of 2 quarters · filed 2024-05-15
$12.34M
10-Q · filed 2024-05-15
$6.45M
derived: sum of 4 quarters · filed 2024-05-15
2022-12-31-$2.38M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-14
$3.83M
10-Q · filed 2024-02-14
-$2.05M
derived: sum of 3 quarters · filed 2024-02-14
$2.49M
derived: sum of 4 quarters · filed 2024-02-14
2022-09-30$6.21M
10-Q · filed 2023-11-14
$326.00K
derived: sum of 2 quarters · filed 2023-11-14
$4.87M
derived: sum of 3 quarters · filed 2023-11-14
$6.20M
derived: sum of 4 quarters · filed 2023-11-14
2022-06-30-$5.89M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12
-$1.35M
derived: sum of 2 quarters · filed 2023-10-12
-$8.00K
derived: sum of 3 quarters · filed 2023-10-12
-$6.53M
10-K · filed 2023-10-12
2022-03-31$4.54M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11
$5.88M
derived: sum of 2 quarters · filed 2023-05-11
-$647.00K
10-Q · filed 2023-05-11
-$427.00K
derived: sum of 4 quarters · filed 2023-05-11
2021-12-31$1.34M
derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-02-21
-$5.19M
10-Q · filed 2023-02-21
-$4.97M
derived: sum of 3 quarters · filed 2023-02-21
-$8.70M
derived: sum of 4 quarters · filed 2023-02-21
2021-09-30-$6.53M
10-Q/A · filed 2023-02-21
-$6.30M
derived: sum of 2 quarters · filed 2023-02-21
-$10.04M
derived: sum of 3 quarters · filed 2023-02-21
-$9.01M
derived: sum of 4 quarters · filed 2023-02-21
2021-06-30$220.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27
-$3.52M
derived: sum of 2 quarters · filed 2022-09-27
-$2.48M
derived: sum of 3 quarters · filed 2022-09-27
-$1.54M
10-K · filed 2022-09-27
2021-03-31-$3.74M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16
-$2.70M
derived: sum of 2 quarters · filed 2022-05-16
-$1.76M
10-Q · filed 2022-05-16
-$1.77M
10-Q · filed 2021-05-17
-$6.39M
derived: sum of 4 quarters · filed 2022-05-16
2020-12-31$1.04M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14
$1.97M
10-Q · filed 2022-02-14
$1.97M
10-Q · filed 2021-02-11
-$2.65M
derived: sum of 3 quarters · filed 2022-02-14
$2.08M
derived: sum of 4 quarters · filed 2022-02-14
2020-09-30$937.00K
10-Q · filed 2021-11-15
$928.89K
10-Q · filed 2020-11-12
-$3.69M
derived: sum of 2 quarters · filed 2021-11-15
$1.04M
derived: sum of 3 quarters · filed 2021-11-15
$4.53M
derived: sum of 4 quarters · filed 2021-11-15
2020-06-30-$4.62M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28
$104.64K
derived: sum of 2 quarters · filed 2021-09-28
$3.60M
derived: sum of 3 quarters · filed 2021-09-28
$3.56M
10-K · filed 2021-09-28
$3.56M
10-K · filed 2020-10-06
2020-03-31$4.73M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-05-17
$8.22M
derived: sum of 2 quarters · filed 2021-05-17
$8.18M
10-Q · filed 2021-05-17
$8.55M
derived: sum of 4 quarters · filed 2021-05-17
2019-12-31$3.49M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-02-11
$3.46M
10-Q · filed 2021-02-11
$3.82M
derived: sum of 3 quarters · filed 2021-02-11
$3.71M
derived: sum of 4 quarters · filed 2021-02-11
2019-09-30-$35.36K
10-Q · filed 2020-11-12
$329.07K
derived: sum of 2 quarters · filed 2020-11-12
$222.94K
derived: sum of 3 quarters · filed 2020-11-12
$945.37K
derived: sum of 4 quarters · filed 2020-11-12
2019-06-30$364.43K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-06
$258.30K
derived: sum of 2 quarters · filed 2020-10-06
$980.73K
derived: sum of 3 quarters · filed 2020-10-06
$1.16M
10-K · filed 2020-10-06
2019-03-31-$106.13K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-05-15
$616.30K
derived: sum of 2 quarters · filed 2020-05-15
$797.58K
10-Q · filed 2020-05-15
$643.88K
derived: sum of 4 quarters · filed 2020-05-15
2018-12-31$722.43K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-02-14
$903.71K
10-Q · filed 2020-02-14
$750.01K
derived: sum of 3 quarters · filed 2020-02-14
$105.05K
derived: sum of 4 quarters · filed 2020-02-14
2018-09-30$181.27K
10-Q · filed 2019-11-14
$27.58K
derived: sum of 2 quarters · filed 2019-11-14
-$617.38K
derived: sum of 3 quarters · filed 2019-11-14
-$451.79K
derived: sum of 4 quarters · filed 2019-11-14
2018-06-30-$153.69K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-09-26
-$798.65K
derived: sum of 2 quarters · filed 2019-09-26
-$633.06K
derived: sum of 3 quarters · filed 2019-09-26
$50.74K
10-K · filed 2019-09-26
2018-03-31-$644.96K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-14
-$479.37K
derived: sum of 2 quarters · filed 2019-05-14
$204.44K
10-Q · filed 2019-05-14
$379.36K
derived: sum of 4 quarters · filed 2019-05-14
2017-12-31$165.59K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-05-14
$849.40K
10-Q · filed 2019-05-14
$1.02M
derived: sum of 3 quarters · filed 2019-05-14
$784.46K
derived: sum of 4 quarters · filed 2019-05-14
2017-09-30$683.81K
10-Q · filed 2018-11-07
$858.73K
derived: sum of 2 quarters · filed 2018-11-07
$618.87K
derived: sum of 3 quarters · filed 2018-11-07
$691.82K
derived: sum of 4 quarters · filed 2018-11-07
2017-06-30$174.92K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-09-06
-$64.94K
derived: sum of 2 quarters · filed 2018-09-06
$8.02K
derived: sum of 3 quarters · filed 2018-09-06
$355.03K
10-K · filed 2018-09-06
2017-03-31-$239.86K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-05-14
-$166.90K
derived: sum of 2 quarters · filed 2018-05-14
$180.11K
10-Q · filed 2018-05-14
$258.26K
derived: sum of 4 quarters · filed 2018-05-14
2016-12-31$72.95K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-02-08
$419.97K
10-Q · filed 2018-02-08
$498.12K
derived: sum of 3 quarters · filed 2018-02-08
$293.93K
derived: sum of 4 quarters · filed 2018-02-08
2016-09-30$347.01K
10-Q · filed 2017-11-09
$425.17K
derived: sum of 2 quarters · filed 2017-11-09
$220.97K
derived: sum of 3 quarters · filed 2017-11-09
$341.51K
derived: sum of 4 quarters · filed 2017-11-09
2016-06-30$78.15K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-08-31
-$126.04K
derived: sum of 2 quarters · filed 2017-08-31
-$5.50K
derived: sum of 3 quarters · filed 2017-08-31
$5.37K
10-K · filed 2017-08-31
2016-03-31-$204.19K
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-05-11
-$83.66K
derived: sum of 2 quarters · filed 2017-05-11
-$72.78K
10-Q · filed 2017-05-11
$83.24K
derived: sum of 4 quarters · filed 2017-05-11
2015-12-31$120.54K
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-02-09
$131.41K
10-Q · filed 2017-02-09
$287.43K
derived: sum of 3 quarters · filed 2017-02-09
$281.56K
derived: sum of 4 quarters · filed 2017-02-09
2015-09-30$10.87K
10-Q · filed 2016-11-07
$166.89K
derived: sum of 2 quarters · filed 2016-11-07
$161.02K
derived: sum of 3 quarters · filed 2016-11-07
2015-06-30$156.02K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-09-01
$150.15K
derived: sum of 2 quarters · filed 2016-09-01
$157.06K
10-K · filed 2016-09-01
2015-03-31-$5.87K
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-05-11
$1.04K
10-Q · filed 2016-05-11
2014-12-31$6.91K
10-Q · filed 2016-02-11
2014-03-31-$24.00K
10-Q · filed 2015-05-19

Similar stocks

Stock NameCountryMarket CapPE Ratio
NextCure, Inc. (NXTC)United States$0.024B-0.15
TherapeuticsMD, Inc. (TXMD)United States$0.024B-117.87
ARTELO BIOSCIENCES, INC. (ARTL)United States$0.023B
KYNTRA BIO, INC. (KYNB)United States$0.028B0.17
Transcode Therapeutics, Inc. (RNAZ)United States$0.029B-0.12
Cocrystal Pharma, Inc. (COCP)United States$0.022B
Hepion Pharmaceuticals, Inc. (HEPA)United States$0.029B-0.62
ATOSSA THERAPEUTICS, INC. (ATOS)United States$0.021B-0.52
IGC Pharma, Inc. (IGC)United States$0.029B-5.98
Neuphoria Therapeutics Inc. (NEUP)United States$0.020B-1.77